News
Insider Monkey on MSN21h
Arcutis’ ZORYVE Receives AAD Recommendation for Adult Atopic DermatitisOn June 26, Arcutis Biotherapeutics Inc. announced that ZORYVE (roflumilast) cream 0.15% received a strong recommendation in ...
Young patients with atopic dermatitis prioritize different treatment goals and have varying preferences from their caregivers.
Apogee Therapeutics (NASDAQ:APGE) stock fell on Monday despite the announcement that it met its main goal in part A of its ...
The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...
[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...
A focused update to AAD’s adult AD guidelines recommends tapinarof, roflumilast, lebrikizumab, and nemolizumab based on ...
A new analysis from US data analytics firm Phesi has raised concerns about the viability of ongoing Phase III trials in ...
AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...
Atopic dermatitis is a very common skin disease found in both adults and children. In fact, up to 10 to 20 percent of the population at some point suffers from atopic dermatitis.
Atopic dermatitis and contact dermatitis may both have certain triggers that set off your flares. If you can avoid your triggers, you may be able to calm skin rashes or even prevent them.
10d
Health on MSNSpongiotic Dermatitis: Symptoms, Causes, and How To Treat ItSpongiotic dermatitis describes skin inflammation that causes swelling, redness, and itching. It's most often associated with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results